Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018

Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018


  • Products Id :- GDME0637EPD
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2018" provides an overview of Cervical Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Cervical Cancer Diagnostic Tests under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Cervical Cancer Diagnostic Tests Overview 7

3 Products under Development 8

3.1 Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 8

3.2 Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 9

3.3 Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 10

3.4 Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 11

3.5 Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 12

4 Cervical Cancer Diagnostic Tests-Pipeline Products under Development by Companies 13

4.1 Cervical Cancer Companies-Pipeline Products by Stage of Development 13

4.2 Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 14

5 Cervical Cancer Diagnostic Tests Companies and Product Overview 15

5.1 Alere Inc Company Overview 15

5.2 Augusta University Company Overview 16

5.3 Becton Dickinson and Co Company Overview 17

5.4 Bio Techne Corp Company Overview 21

5.5 BioAffinity Technologies, Inc. Company Overview 22

5.6 BioMark Diagnostics Inc. Company Overview 23

5.7 BioMark Technologies Inc Company Overview 24

5.8 Cepheid Company Overview 25

5.9 China Sky One Medical Inc Company Overview 26

5.10 Cytosystems Ltd Company Overview 27

5.11 Enzo Biochem Inc Company Overview 28

5.12 GenomicTree Inc Company Overview 29

5.13 GRANT Life Sciences, Inc. Company Overview 31

5.14 Louisville Bioscience, Inc. Company Overview 32

5.15 MDNA Life Sciences Inc Company Overview 33

5.16 MDxHealth SA Company Overview 34

5.17 Milagen Inc Company Overview 35

5.18 Olympia Diagnostics, Inc Company Overview 36

5.19 Oncgnostics GmbH Company Overview 38

5.20 ONCOVEDA Cancer Research Center Company Overview 40

5.21 Precision Biologics Inc Company Overview 41

5.22 US Biomarkers Inc Company Overview 42

5.23 XEPTAGEN SpA Company Overview 43

6 Cervical Cancer Diagnostic Tests Recent Developments 44

6.1 Jun 27, 2018: BD, Heart to Heart International and the NAFC Announce 2018 Grantees for a Multi-Year Point of Care Testing Initiative to Improve Patient Outcomes 44

6.2 Jun 12, 2018: Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer 45

6.3 Jun 12, 2018: Cancer Genetics Appoints Michael McCartney As Chief Commercial Officer 45

6.4 Jun 05, 2018: Study Finds Older Patients Who Undergo Mammography Also Are More Likely to Pursue Other Preventive Tests 46

6.5 Jun 01, 2018: BD Appoints John DeFord As Chief Technology Officer 47

6.6 May 17, 2018: Quest Diagnostics adds Helen Torley to Board of Directors 47

6.7 May 15, 2018: Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates 48

6.8 May 14, 2018: bioAffinity Technologies Welcomes Peter S. Knight to Board of Directors 50

6.9 May 07, 2018: Forbes Names Quest Diagnostics One of America's Best Large Employers 50

6.10 May 06, 2018: Kaskela Law: Shareholder Class Action Filed Against Cancer Genetics 51

6.11 May 03, 2018: BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance 51

7 Appendix 94

7.1 Methodology 94

7.2 About GlobalData 97

7.3 Contact Us 97

7.4 Disclaimer 97

1.2 List of Figures

Figure 1: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 8

Figure 2: Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 9

Figure 3: Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 10

Figure 4: Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 11

Figure 5: Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 12

1.1 List of Tables

Table 1: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 8

Table 2: Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 9

Table 3: Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 10

Table 4: Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 11

Table 5: Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 12

Table 6: Cervical Cancer Companies-Pipeline Products by Stage of Development 13

Table 7: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 14

Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: NMP179 Test-Product Status 15

Table 10: NMP179 Test-Product Description 15

Table 11: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Folate Receptor Biomarker Test-Cervical Cancer Diagnostic Tests-Product Status 16

Table 13: Folate Receptor Biomarker Test-Cervical Cancer Diagnostic Tests-Product Description 16

Table 14: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: BD SurePath Plus Molecular Pap Test System-Product Status 17

Table 16: BD SurePath Plus Molecular Pap Test System-Product Description 17

Table 17: Biomarker Test-Cervical Cancer Diagnostic Tests-Product Status 18

Table 18: Biomarker Test-Cervical Cancer Diagnostic Tests-Product Description 18

Table 19: Becton Dickinson and Co-Ongoing Clinical Trials Overview 19

Table 20: BD SurePath Plus Molecular Pap Test System-Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil: UH3-Brazil 20

Table 21: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 21

Table 22: RNAscope HPV Assay-Cervical Cancer Diagnostic Tests-Product Status 21

Table 23: RNAscope HPV Assay-Cervical Cancer Diagnostic Tests-Product Description 21

Table 24: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

Table 25: CyPath Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Status 22

Table 26: CyPath Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Description 22

Table 27: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

Table 28: Metabolomics-based Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Status 23

Table 29: Metabolomics-based Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Description 23

Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 31: Biomarker Assay-Cervical Cancer Diagnostic Tests-Product Status 24

Table 32: Biomarker Assay-Cervical Cancer Diagnostic Tests-Product Description 24

Table 33: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 25

Table 34: Xpert Molecular PAP Assay-Product Status 25

Table 35: Xpert Molecular PAP Assay-Product Description 25

Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 37: Diagnostic Kit-Carcinoma Cervix-Product Status 26

Table 38: Diagnostic Kit-Carcinoma Cervix-Product Description 26

Table 39: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

Table 40: Laboratory-Based Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Status 27

Table 41: Laboratory-Based Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Description 27

Table 42: Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview 28

Table 43: p16 Biomarker-Cervical Cancer Diagnostic Tests-Product Status 28

Table 44: p16 Biomarker-Cervical Cancer Diagnostic Tests-Product Description 28

Table 45: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 46: EarlyTect Cervical Cancer Diagnostic Tests-Product Status 29

Table 47: EarlyTect Cervical Cancer Diagnostic Tests-Product Description 29

Table 48: Screening Test-Cervical Cancer Diagnostic Tests-Product Status 30

Table 49: Screening Test-Cervical Cancer Diagnostic Tests-Product Description 30

Table 50: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31

Table 51: Serum-Based Test-Cervical Cancer Diagnostic Tests-Product Status 31

Table 52: Serum-Based Test-Cervical Cancer Diagnostic Tests-Product Description 31

Table 53: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

Table 54: Cervical Cancer Remission pT Test-Product Status 32

Table 55: Cervical Cancer Remission pT Test-Product Description 32

Table 56: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Table 57: Cervical Mitomic Test-Product Status 33

Table 58: Cervical Mitomic Test-Product Description 33

Table 59: MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 34

Table 60: ClinicalMDx-Cervical Cancer Diagnostic Tests-Product Status 34

Table 61: ClinicalMDx-Cervical Cancer Diagnostic Tests-Product Description 34

Table 62: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 63: Immunoassay-Cervical Cancer Diagnostic Tests-Product Status 35

Table 64: Immunoassay-Cervical Cancer Diagnostic Tests-Product Description 35

Table 65: Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview 36

Table 66: Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Status 36

Table 67: Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Description 36

Table 68: Prognostic Test-Cervical Cancer Diagnostic Tests-Product Status 37

Table 69: Prognostic Test-Cervical Cancer Diagnostic Tests-Product Description 37

Table 70: Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 38

Table 71: GynTect-Product Status 38

Table 72: GynTect-Product Description 38

Table 73: GynTect 2.0-Product Status 39

Table 74: GynTect 2.0-Product Description 39

Table 75: ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 40

Table 76: HPV Companion Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Status 40

Table 77: HPV Companion Diagnostic Test-Cervical Cancer Diagnostic Tests-Product Description 40

Table 78: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Table 79: Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Status 41

Table 80: Diagnostic Assay-Cervical Cancer Diagnostic Tests-Product Description 41

Table 81: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 42

Table 82: Blood-Based Biomarker-Cervical Cancer Diagnostic Tests-Product Status 42

Table 83: Blood-Based Biomarker-Cervical Cancer Diagnostic Tests-Product Description 42

Table 84: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 43

Table 85: SCCA-IgM Kit-Cervical Cancer Diagnostic Tests-Product Status 43

Table 86: SCCA-IgM Kit-Cervical Cancer Diagnostic Tests-Product Description 43

Table 87: Glossary 96

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alere Inc

Augusta University

Becton Dickinson and Co

Bio Techne Corp

BioAffinity Technologies, Inc.

BioMark Diagnostics Inc.

BioMark Technologies Inc

Cepheid

China Sky One Medical Inc

Cytosystems Ltd

Enzo Biochem Inc

GenomicTree Inc

GRANT Life Sciences, Inc.

Louisville Bioscience, Inc.

MDNA Life Sciences Inc

MDxHealth SA

Milagen Inc

Olympia Diagnostics, Inc

Oncgnostics GmbH

ONCOVEDA Cancer Research Center

Precision Biologics Inc

US Biomarkers Inc

XEPTAGEN SpA

Alere Inc, NMP179 Test; Augusta University, Folate Receptor Biomarker Test - Cervical Cancer; Becton Dickinson and Co, BD SurePath Plus Molecular Pap Test System; Becton Dickinson and Co, Biomarker Test - Cervical Cancer; Bio Techne Corp, RNAscope HPV Assay - Cervical Cancer; BioAffinity Technologies, Inc., CyPath Diagnostic Assay - Cervical Cancer; BioMark Diagnostics Inc., Metabolomics-based Diagnostic Assay - Cervical Cancer; BioMark Technologies Inc, Biomarker Assay - Cervical Cancer; Cepheid, Xpert Molecular PAP Assay; China Sky One Medical Inc, Diagnostic Kit - Carcinoma Cervix; Cytosystems Ltd, Laboratory-Based Diagnostic Test - Cervical Cancer; Enzo Biochem Inc, p16 Biomarker - Cervical cancer; GenomicTree Inc, EarlyTect Cervical Cancer; GenomicTree Inc, Screening Test - Cervical Cancer; GRANT Life Sciences, Inc., Serum-Based Test - Cervical Cancer; Louisville Bioscience, Inc., Cervical Cancer Remission pT Test; MDNA Life Sciences Inc, Cervical Mitomic Test; MDxHealth SA, ClinicalMDx - Cervical Cancer; Milagen Inc, Immunoassay - Cervical Cancer; Olympia Diagnostics, Inc, Diagnostic Test - Cervical Cancer; Olympia Diagnostics, Inc, Prognostic Test - Cervical Cancer; Oncgnostics GmbH, GynTect; Oncgnostics GmbH, GynTect 2.0; ONCOVEDA Cancer Research Center, HPV Companion Diagnostic Test - Cervical Cancer; Precision Biologics Inc, Diagnostic Assay - Cervical Cancer; US Biomarkers Inc, Blood-Based Biomarker - Cervical Cancer; XEPTAGEN SpA, SCCA - IgM Kit - Cervical Cancer

select a license
Single User License
USD 2500 INR 178325
Site License
USD 5000 INR 356650
Corporate User License
USD 7500 INR 534975

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com